Silihan lan utang jangka dawa perusahaan PainReform Limited (PRFX)

PainReform Ltd. (PRFX) protects its positions with patents for the Plex03 system for managing postoperative pain, operating under the strictest FDA oversight. Slow-release technology allows the company to maintain pricing power for its services provided to clinics. The share price retrospective with the 0.00 indicator confirms the current status of the business. The absence of commercial products and reliance on investment make future growth hostage to the results of clinical trials.

Long-term debt reflects the aggregate of obligations with a maturity exceeding one year, determining the issuer's financial stability. An increase in this metric signals a rising debt load and potential loan servicing costs. By analyzing the long-term debt indicator, an investor assesses the default risk should the cost of capital change. For PainReform Ltd. (PRFX), this trend is critical due to the vulnerability of raw material supply chains. Geopolitical barriers could restrict liquidity, complicating the fulfillment of long-term obligations.